Remove Bioavailability Remove Genotoxicity Remove In-Vivo Remove Research
article thumbnail

The Composition and Value of a Portfolio Analysis

Camargo

Pediatric Research Equity Act (PREA) Requirements. Clinical pharmacology may also involve comparative bioavailability analyses, which are generally required for drug formulation bridging studies, to demonstrate bioequivalence. However, they may generate undifferentiated labels that are not conducive to commercial success.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We

Trials 69